Cargando…

SUN-093 Prospective Clinical Assessment Study in Children with Achondroplasia: The PROPEL Trial

BACKGROUND: Achondroplasia (ACH) is the most common non-lethal form of skeletal dysplasia, affecting between 1 in 15,000 to 1 in 30,000 live births [Horton et al. 2007; Waller et al. 2008]. Children and adults with ACH have disproportionate short stature, with a final height of approximately 131 cm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Savarirayan, Ravi, Kannu, Peter, Dambkowski, Carl L, Rogoff, Daniela, Irving, Melita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Pediatric Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209755/ http://dx.doi.org/10.1210/jendso/bvaa046.557

Ejemplares similares

PSAT106 Infigratinib in Children with Achondroplasia: Design of the PROPEL, PROPEL2 and PROPEL OLE Studies
por: Muslimova, Elena, et al.
Publicado: (2022)

RF26 | PMON326 Medical History of Children Enrolled in PROPEL: A Prospective Clinical Assessment Study in Children with Achondroplasia
por: Irving, Melita, et al.
Publicado: (2022)

THU165 PROPEL, PROPEL 2 And PROPEL OLE Studies Of Infigratinib In Children With Achondroplasia: Design And Status Of 3 Ongoing Trials
por: Savarirayan, Ravi, et al.
Publicado: (2023)

PSAT105 Evaluation of Body Mass Index and Metabolic Parameters in Children with Achondroplasia Participating in the PROPEL Study
por: Rogoff, Daniela, et al.
Publicado: (2022)

SUN-087 FGFR-Selective Tyrosine Kinase Inhibitors, Such as Infigratinib, Show Potency and Selectivity for FGFR3 at Pharmacologically Relevant Doses for the Potential Treatment of Achondroplasia
por: Dobscha, Katherine, et al.
Publicado: (2020)

Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies
por: Savarirayan, Ravi, et al.
Publicado: (2022)

OR27-03 Oral Infigratinib Treatment Is Well Tolerated And Significantly Increases Height Velocity In Children With Achondroplasia: Month 6 Results From The PROPEL 2 Dose-finding Study
por: Savarirayan, Ravi, et al.
Publicado: (2023)

SUN-101 Support for a New Therapeutic Approach of Using a Low-Dose FGFR Tyrosine Kinase Inhibitor (Infigratinib) for Achondroplasia
por: Demuynck, Benoit, et al.
Publicado: (2020)

THU181 Evaluation Of Bone Mineral Density In A Cohort Of Children With ACH Participating In The PROPEL 2 Study Of Infigratinib
por: Savarirayan, Ravi, et al.
Publicado: (2023)

PSAT103 Qualitative Research in Children with Achondroplasia and Parents of Children with Achondroplasia: Medical Challenges and Impacts
por: Muslimova, Elena, et al.
Publicado: (2022)

SAT-LB18 A Randomized Controlled Trial of Vosoritide in Children With Achondroplasia
por: Savarirayan, Ravi, et al.
Publicado: (2020)

LBMON196 A Randomized Controlled Trial Of Vosoritide In Infants And Toddlers With Achondroplasia
por: Savarirayan, Ravi, et al.
Publicado: (2022)

PSAT102 Qualitative Research in Children and Parents of Children with Achondroplasia to Cognitively Debrief Three Patient-Reported Outcome Measures and Confirm the Content Validity of a Clinical-Assessed Measure
por: Muslimova, Elena, et al.
Publicado: (2022)

Persistent and Stable Growth Promoting Effects of Vosoritide in Children With Achondroplasia for up to 2 Years: Results From the Ongoing Phase 3 Extension Study
por: Savarirayan, Ravi, et al.
Publicado: (2021)

Design and Baseline Demographics of a Five-Year, Multi-National Observational Cohort Study of Children With Achondroplasia (ACHieve Study)
por: Ward, Leanne M, et al.
Publicado: (2021)

THU156 Significantly Improved Annual Height Velocity With Once-Weekly TransCon CNP In Children With Achondroplasia: The ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial
por: Savarirayan, Ravi, et al.
Publicado: (2023)

MON-093 Pleuropulmonary Blastoma and Multinodular Goiter in a 22 Yr Old Male with DICER1 Syndrome
por: Lhamu, Ugen, et al.
Publicado: (2020)

Pharmacokinetics and Exposure–Response of Vosoritide in Children with Achondroplasia
por: Chan, Ming Liang, et al.
Publicado: (2021)

SAT-093 Two Cases of Autosomal Dominant Familial Central Diabetes Insipidus: A Novel Variant in Neurophysin II Region of AVP Gene
por: Ramirez, Biochemist, Pablo, et al.
Publicado: (2020)

SUN-248 Growth Hormone Deficiency (GHD): Assessing Burden of Treatment in Children and Adolescents
por: Brod, Meryl, et al.
Publicado: (2019)

Hearing loss in Norwegian adults with achondroplasia
por: Fredwall, Svein O., et al.
Publicado: (2021)

Experiences of children and adolescents living with achondroplasia and their caregivers
por: Shediac, Renée, et al.
Publicado: (2022)

SUN-067 Pituitary Dysfunction in Children with Ectopic Posterior Pituitary
por: Naji, Ghada, et al.
Publicado: (2020)

Evidence of feedback regulation of C-type natriuretic peptide during Vosoritide therapy in Achondroplasia
por: Prickett, Timothy C. R., et al.
Publicado: (2021)

Optimal management of complications associated with achondroplasia
por: Ireland, Penny J, et al.
Publicado: (2014)

Australian guidelines for the management of children with achondroplasia
por: Tofts, Louise J, et al.
Publicado: (2023)

SUN-075 A Guide to Professional Development: Funding Your Research Through NICHD
por: Eisenberg, Esther, et al.
Publicado: (2020)

SUN-076 Somatic and Neurodevelopmental Outcome and Muscle Tone in 5 to 9 Year Old Children Born After Intracytoplasmic Sperm Injection
por: Snajderova, Marta, et al.
Publicado: (2020)

SUN-LB17 The Association of Growth Hormone Treatment in Children With Short Stature With Idiopathic Scoliosis
por: Nam, Hyo-Kyoung, et al.
Publicado: (2020)

OR21-05 Low-dose Infigratinib, An Oral Selective Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, Demonstrates Activity In Murine Models Of Achondroplasia And Hypochondroplasia
por: Muslimova, Elena, et al.
Publicado: (2023)

SUN-244 Birth and Perinatal Characteristics of Children with Congenital GH Deficiency (GHD) Due to Abnormal Pituitary Development: Data from a Prospective, Multinational Observational Study
por: Child, Christopher, et al.
Publicado: (2019)

SUN-258 Prediction of Height Two Years after Start Treatment in Children with Growth Hormone Deficiency
por: van Dommelen, Paula, et al.
Publicado: (2019)

SUN-287 Pituitary Gigantism Presenting as Anxiety
por: Velasco, Jacqueline, et al.
Publicado: (2019)

SUN-055 Prenatal Exposure to Artificial Sweeteners
por: Halasa, Brianna C, et al.
Publicado: (2020)

Results and complications of bilateral limb lengthening in achondroplasia: a retrospective analysis
por: Verdoni, Fabio, et al.
Publicado: (2023)

FRI093 Severe Hypertriglyceridemia Post Liver Transplant- A Multifactorial Disorder
por: Saand, Aisha R, et al.
Publicado: (2023)

SUN-277 Severe Hyperglycemia in the Setting of Hypernatremic Dehydration
por: Gupta, Meenal, et al.
Publicado: (2019)

SUN-241 Understanding and Communication of DSD in Patients' Perspectives
por: Lousada Quintão, Lia, et al.
Publicado: (2019)

SUN-259 Recombinant Growth Hormone Therapy for Children with Turner Syndrome in Korea: A Phase III Randomized Trial
por: Kim, Jinsup, et al.
Publicado: (2019)

Current knowledge of medical complications in adults with achondroplasia: A scoping review
por: Fredwall, Svein O., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a6n3k7stj55mm7q60lgmri0du7